Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears Coherent's glaucoma laser:

This article was originally published in Clinica

Executive Summary

Coherent has gained FDA 510(k) clearance to market its Selecta 7000 glaucoma laser system in the US. The device is designed to perform selective laser trabeculoplasty (SLT) for the treatment of open angle glaucoma, which the Santa Clara, California company says is the leading cause of preventable blindness in US citizens over the age of 40. SLT reduces intraocular pressure without causing damage to non-melanin-containing cells and the trabecular meshwork structure, adds Coherent.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts